Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05575492 · ClinicalTrials.gov registry record · Phase 1
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
A Phase 1 study of Cytomegalovirus, sponsored by ModernaTX.
- Active
- Registry status
- Phase 1
- Development phase
- 873
- Enrollment target
- 20
- Study locations
NCT05575492: Active Phase 1 study of Cytomegalovirus, sponsored by ModernaTX.
NCT05575492 is a Phase 1 study of Cytomegalovirus that is active but no longer recruiting, run by ModernaTX. The registered enrollment target is 873 participants, above the 48-participant average among 5 other Cytomegalovirus trials with a reported enrollment target (1719% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05575492, a Phase 1 study of Cytomegalovirus, is active but no longer recruiting, sponsored by ModernaTX.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 873 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of study is to evaluate the safety and immunogenicity of different dose levels of mRNA-1647 versus control in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive female and male participants 9 to 15 years of age. In addition, mRNA-1647 will be evaluated in female participants 16 to 25 years as a comparator cohort.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL mRNA-1647
Study Locations (20)
Florida
- Prohealth Research Center - Doral
- University of Florida Jacksonville - Jacksonville
- Clinical Neurosciences Solutions Inc. (Orlando-East South St) - Orlando
- Palm Harbor Dermatology - Tampa
- Santos Research Center - Tampa
California
- Paradigm Clinical Research Institute Inc - ClinEdge - PPDS - La Mesa
- Velocity Clinical Research - San Diego - PPDS - La Mesa
- Benchmark Research - Sacramento -Hypercore- PPDS - Sacramento
Maryland
- University of Maryland School of Medicine - Baltimore
- The Pediatric Centre - Columbia
- The Pediatric Centre of Frederick - Frederick
Georgia
- Children's Healthcare of Atlanta - Atlanta
- iResearch Atlanta - CenExel - PPDS - Decatur
Louisiana
- Benchmark Research - Covington - HyperCore- PPDS - Covington
- Tulane Medical Center - New Orleans
Colorado
- Tekton Research - Fort Collins - Platinum - PPDS - Fort Collins
District of Columbia
- Velocity Clinical Research (Washington)- PPDS - Washington D.C.
Idaho
- Clinical Research Prime - ClinEdge - PPDS - Idaho Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 873 participants |
| Start Date | 2022-11-07 |
| Est. Completion | 2027-01-15 |
| Phase | Phase 1 |
What the registry record for NCT05575492 still lists
NCT05575492 is an interventional study that assigns participants to a tested intervention. The registered 873 participants enrollment target is mid-sized for trials with a published cap, above the 48-participant average among 5 other Cytomegalovirus trials with a reported enrollment target (1719% higher).
The record links to 1 condition, with Cytomegalovirus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05575492 names 20 study sites across 10 states, led by Florida, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT05575492 about?
NCT05575492 is a clinical study titled "A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age". The main purpose of study is to evaluate the safety and immunogenicity of different dose levels of mRNA-1647 versus control in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive female and male participants 9 to 15 years of age. In addition, mRNA-1647 will be evaluated in female partici...
What is the current status of trial NCT05575492?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 873 participants. The study started on 2022-11-07. Estimated completion is 2027-01-15.
What conditions does trial NCT05575492 study?
This clinical trial studies the following conditions: Cytomegalovirus.
What interventions are being tested in trial NCT05575492?
The interventions under investigation include: Placebo (OTHER), mRNA-1647 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05575492?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05575492 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegalovirus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age
COMPLETED · Phase 1
-
Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation
RECRUITING · Phase 2
-
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
RECRUITING · Early Phase 1
-
Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)
RECRUITING · Phase 4
-
Effect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Burned Patients
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04097145 · 870 participants · NA
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
- NCT07076199 · 877 participants · Phase 3
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
- NCT06822790 · 869 participants · Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- NCT06627647 · 878 participants · Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI